Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1391 ARTÍCULOS , VIENDO DEL 31 AL 45

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

Guzior N, Wieckowska A, Panek D, Malawska B.

Curr Med Chem. 2015;22(3):373-404. doi: 10.2174/0929867321666141106122628.

The evolving biology of microglia in Alzheimer's disease

Malm TM, Jay TR, Landreth GE.

Neurotherapeutics. 2015 Jan;12(1):81-93. doi: 10.1007/s13311-014-0316-8.

Frailty and cognitive decline: how do they relate?

Canevelli M, Cesari M, van Kan GA.

Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):43-50. doi: 10.1097/MCO.0000000000000133.

Mediterranean diet and cognitive health: an update of available knowledge

Feart C, Samieri C, Barberger-Gateau P.

Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):51-62. doi: 10.1097/MCO.0000000000000131.

Benzodiazepine use and risk for Alzheimer disease

Salzman C, Shader RI.

J Clin Psychopharmacol. 2015 Feb;35(1):1-3. doi: 10.1097/JCP.0000000000000247.

Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease

Ryan NS, Lashley T, Revesz T, Dantu K, Fox NC, Morris HR.

J Alzheimers Dis. 2015;44(4):1069-74. doi: 10.3233/JAD-142325.

Neuropathological changes in aging brain

Xekardaki A, Kövari E, Gold G, Papadimitropoulou A, Giacobini E, Herrmann F, Giannakopoulos P, Bouras C.

Adv Exp Med Biol. 2015;821:11-7. doi: 10.1007/978-3-319-08939-3_6.

The role of chemical engineering in medicinal research including Alzheimer's

Kontogeorgis GM.

Adv Exp Med Biol. 2015;821:57-62. doi: 10.1007/978-3-319-08939-3_10.

Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease

Friedman LG, Qureshi YH, Yu WH.

Neurotherapeutics. 2015 Jan;12(1):94-108. doi: 10.1007/s13311-014-0320-z.

Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy

Fazili NA, Naeem A, Ashraf GM, Hua GS, Kamal MA.

Curr Drug Metab. 2015;16(5):346-53. doi: 10.2174/1389200215999141125115749.

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 10.1097/WAD.0000000000000073.

Alzheimer's disease and other dementias: advances in 2014

Bateman R.

Lancet Neurol. 2015 Jan;14(1):4-6. doi: 10.1016/S1474-4422(14)70301-1.

The contribution of proteinase-activated receptors to intracellular signaling, transcellular transport and autophagy in Alzheimer's disease

Matěj R, Rohan Z, Holada K, Olejár T.

Curr Alzheimer Res. 2015;12(1):2-12. doi: 10.2174/1567205012666141218123202.

SAIDO learning as a cognitive intervention for dementia care: a preliminary study

Kawashima R, Hiller DL, Sereda SL, Antonczak M, Serger K, Gannon D, Ito S, Otake H, Yunomae D, Kobayashi A, Muller C, Murata H, FallCreek S.

J Am Med Dir Assoc. 2015 Jan;16(1):56-62. doi: 10.1016/j.jamda.2014.10.021.

Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities

Caldwell CC, Yao J, Brinton RD.

Neurotherapeutics. 2015 Jan;12(1):66-80. doi: 10.1007/s13311-014-0324-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias